论文部分内容阅读
Background and Purpose -Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study. To determine whether Clopidogrel with aspirin (C+ASA) will produce more potent platelet inhibition than aspirin alone (ASA) in patients after ischemic stroke, we conducted the Plavix Use for Treatment of Stroke trial. Methods -Seventy patients after ischemic stroke were randomly assigned to C+ASA or ASA groups. Platelet studies included aggregometry; cartridge-based analyzers; expression of PECAM-1, P-selectin, GP IIb/IIIa (antigen and activity), vitronectin receptor, and formation of platelet-leu-kocyte microparticles by flow cytometry. Platelet tests were performed at baseline and after 30 days after randomization. Results -There were no deaths, hospitalizations, or serious adverse events. There were no differences in the baseline platelet characteristics between C+ASA and ASA groups, or significant changes in platelet parameters in the ASA group, except diminished collagen-induced aggregation (P=0.001). In contrast, therapy with C+ASA resulted in a significant inhibition of platelet activity assessed by ADP-(P=0.00001) and collagen-induced (P=0.02) aggregation; closure time prolongation (P=0.03), and reduction of platelet activation units with Ultegra (P=0.00001); expression of PECAM-1 (P=0.01), and GP IIb/IIIa activity with PAC-1 (P=0.02) when compared with ASA group. Therapy with C+ASA also resulted in the reduced formation of platelet-leukocyte microparticles (P=0.02). Conclusion -Treatment with C+ASA for 1 month provides significantly greater inhibition of platelet activity than ASA alone in patients after recent ischemic stroke in the frame of the small randomized trial. u001a
Background and Purpose-Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study. To determine whether Clopidogrel with aspirin (C + ASA) will produce more-potent platelet inhibition than aspirin alone (ASA) in patients after ischemic stroke, we conducted the Plavix Use for Treatment of Stroke trial. Methods-Seventy patients after ischemic stroke were randomly assigned to C + ASA or ASA groups. Platelet studies included aggregometry; cartridge-based analyzers; expression of PECAM-1, P-selectin, GP IIb / IIIa (antigen and activity), vitronectin receptor, and formation of platelet-leu-kocyte microparticles by flow cytometry. Platelet tests were performed at baseline and after 30 days-after randomization. Results -There were no deaths, hospitalizations, or serious adverse events. There were no differences in the baseline platelet characteristics between C + ASA and ASA groups, or significant changes in platelet parameters in the ASA group, except diminished collagen-induced aggregation (P = 0.001). In contrast, therapy with C + ASA resulted in a significant inhibition of platelet activity assessed by ADP- ( Collapse of platelet activation units with Ultegra (P = 0.00001); and Collagen-induced (P = 0.02) aggregation; closure time prolongation (P = 0.03) Therapy with C + ASA also resulted in reduced formation of platelet-leukocyte microparticles (P = 0.02). Conclusion -Treatment with C + ASA for (P = 0.02) when compared with ASA group. 1 month provides significantly greater inhibition of platelet activity than ASA alone in patients after recent ischemic stroke in the frame of the small randomized trial. U001a